Zantrene (bisantrene) / Race Oncology 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
  • ||||||||||  Zantrene (bisantrene) / Race Oncology, brequinar (DUP 785) / BMS, Clear Creek Bio
    Hnrnpc and m6a RNA Methylation Control Oncogenic Transcription and Metabolism in T-Cell Leukemia (Marriott Grand Ballroom 8-9 (Marriott Marquis San Diego Marina)) -  Nov 6, 2024 - Abstract #ASH2024ASH_1944;    
    Combining FTO inhibitors with dexamethasone and other chemotherapeutic agents demonstrated synergy in inhibiting T-ALL. These findings indicate that T-ALL exhibits dysregulated RNA methylation and demonstrate the potential of targeting HNRNPC and FTO as therapeutic strategies in T-ALL.
  • ||||||||||  Zantrene (bisantrene) / Race Oncology
    Journal:  Metal-Enhanced Aggregation-Induced Emission Strategy for the HIV-I RNA-Binding Ligand Assay. (Pubmed Central) -  Apr 9, 2022   
    When this system was adopted to test four candidate ligands, it was found that bisantrene had a favorable TAR RNA-binding ability. The proposed AIE-MEF strategy not only provides a sensitive and reliable method for the TAR RNA-binding ligand assay but also can avoid the influence of ligands on fluorescent detection in the conventional displacement assay.
  • ||||||||||  Zantrene (bisantrene) / Race Oncology
    New P2 trial, Combination therapy:  Bisantrene Combination for Resistant AML (clinicaltrials.gov) -  Aug 3, 2021   
    P2,  N=29, Recruiting, 
  • ||||||||||  bisantrene (CL-216942) / Race Oncology
    Clinical, P2 data, Journal:  A phase II study of Bisantrene in patients with relapsed/refractory acute myeloid leukemia. (Pubmed Central) -  Jul 30, 2021   
    P2
    The proposed AIE-MEF strategy not only provides a sensitive and reliable method for the TAR RNA-binding ligand assay but also can avoid the influence of ligands on fluorescent detection in the conventional displacement assay. In view of the observed low toxicity, a follow-up study combining bisantrene with complementary anti-leukemic therapy is planned.
  • ||||||||||  bisantrene (CL-216942) / Race Oncology
    [VIRTUAL] A Phase II Study of Bisantrene in Patients with Relapsed/Refractory Acute Myeloid Leukemia (Poster Hall (Virtual Meeting)) -  Nov 5, 2020 - Abstract #ASH2020ASH_816;    
    P2
    Given its marked activity in patients with leukemia cutis, chroromas and CNS disease, we speculate that bisantrene-based chemotherapy may have a significant applicability in patients with extramedullary disease. In view of the observed efficacy and low related toxicity, a follow-up study combining bisantrene with complementary anti-leukemic therapy is planned.
  • ||||||||||  Zantrene (bisantrene) / Race Oncology
    Trial completion, Trial completion date, Trial primary completion date:  Bisantrene for Relapsed /Refractory AML (clinicaltrials.gov) -  Aug 8, 2020   
    P2,  N=10, Completed, 
    In view of the observed efficacy and low related toxicity, a follow-up study combining bisantrene with complementary anti-leukemic therapy is planned. Recruiting --> Completed | Trial completion date: Dec 2021 --> Jul 2020 | Trial primary completion date: Sep 2021 --> May 2020
  • ||||||||||  Zantrene (bisantrene) / Race Oncology
    Enrollment open:  Bisantrene for Relapsed /Refractory AML (clinicaltrials.gov) -  Jan 21, 2020   
    P2,  N=12, Recruiting, 
    Recruiting --> Completed | Trial completion date: Dec 2021 --> Jul 2020 | Trial primary completion date: Sep 2021 --> May 2020 Not yet recruiting --> Recruiting
  • ||||||||||  Zantrene (bisantrene) / Race Oncology
    Phase classification:  Bisantrene for Relapsed /Refractory AML (clinicaltrials.gov) -  Apr 10, 2019   
    P2,  N=12, Not yet recruiting, 
    Not yet recruiting --> Recruiting Phase classification: P3 --> P2
  • ||||||||||  Zantrene (bisantrene) / Race Oncology
    Trial completion date, Trial initiation date, Trial primary completion date:  Bisantrene for Relapsed /Refractory AML (clinicaltrials.gov) -  Apr 2, 2019   
    P3,  N=12, Not yet recruiting, 
    Phase classification: P3 --> P2 Trial completion date: Mar 2022 --> Dec 2021 | Initiation date: Mar 2019 --> Sep 2019 | Trial primary completion date: Mar 2021 --> Sep 2021
  • ||||||||||  Zantrene (bisantrene) / Race Oncology
    New P2 trial, New P3 trial:  Bisantrene for Relapsed /Refractory AML (clinicaltrials.gov) -  Jan 29, 2019   
    P3,  N=12, Not yet recruiting,